JOMMI, CLAUDIO
JOMMI, CLAUDIO
Dipartimento di Scienze del Farmaco
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system
2021-01-01 Riva, S.; Efficace, F.; Di Maio, M.; Bryce, J.; Del Campo, L.; De Lorenzo, F.; Frontini, L.; Giannarelli, D.; Gitto, L.; Iannelli, E.; Jommi, C.; Montesarchio, V.; Traclo, F.; Vaccaro, C. M.; Arenare, L.; Canzanella, G.; Gimigliano, A.; Romano, F.; Savio, A.; Sparavigna, L.; Piccirillo, M. C.; Guizzaro, L.; Gallo, C.; Perrone, F.
Accordi di managed market entry (risk-sharing): razionale e tendenze evolutive nel SSN
2012-01-01 Jommi, Claudio
Accounting and funding of pharmaceuticals. Purpose, structure and management of the File F in nine Italian regions
2016-01-01 Costa, F.; Armeni, P.; Otto, M. H.; Amoroso, N.; Jommi, C.
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration
2022-01-01 Finch, Aureliano Paolo; Meregaglia, Michela; Ciani, Oriana; Roudijk, Bram; Jommi, Claudio
An Introduction to Economic Evaluation of Health Care Programs
2017-01-01 Jommi, C.
An overview of market access agreements
2016-01-01 Toumi, M.; Zard, J.; Abdallah, I. B.; Jommi, C.; Cohen, J.
Analisi di impatto sul budget di WatchmanTM, dispositivo per la prevenzione tromboembolica nei pazienti con fibrillazione atriale
2013-01-01 Jommi, Claudio; A., Iorio; L., Crippa; A., Gelera; G., Senatore
Biosimilari
2010-01-01 Jommi, Claudio
Biosimilari
2010-01-01 Jommi, Claudio
Biosimilari. Aspetti Economici e prospettive per il mercato italiano
2010-01-01 Jommi, Claudio
Budget impact analysis of efavirenz daily dose reduction at the Verona University Hospital
2014-01-01 Costa, E.; Biasi, V.; Concia, E.; Jommi, C.; Lattuada, E.; Manfre, S.; Venturini, F.; Lanzafame, M.
Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
2018-01-01 Rognoni, Carla; Bertolani, Arianna; Jommi, Claudio
CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions
2022-01-01 Jommi, C.; Bramanti, S.; Pani, M.; Ghirardini, A.; Santoro, A.
Clinical Management of Chronic Kidney Disease Patients in Italy: Results from the IRIDE Study
2018-01-01 Cozzolino, M.; Bolasco, P.; Ronco, C.; Conte, G.; Mene, P.; Mereu, M. C.; Di Luca, M.; Roccatello, D.; Rosati, A.; Jommi, C.; Costanzo, A. M.; Gualberti, G.; Di Luzio Paparatti, U.; Remuzzi, G.
Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service
2020-01-01 Armeni, P.; Borsoi, L.; Fornaro, G.; Jommi, C.; Grossi, F.; Costa, F.
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service
2020-01-01 Armeni, P.; Borsoi, L.; Fornaro, G.; Jommi, C.; Colombo, N.; Costa, F.
Costs and outcome of care in subjects with a severe mental disorder
2003-01-01 Percudani, M.; Gerzeli, S.; Massagrandi, R.; Jommi, C.; Fattore, G.; Cerati, G.; Contini, A.
Costs and outcome of care in subjects with severe mental disorders
2003-01-01 Percudani, M; Gerzeli, S; Massagrandi, R; Jommi, Claudio; Fattore, G; Cerati, G; Contini, A.
Costs of patients suffering from multiple sclerosis in piedmont region: Evidence from administrative databases
2012-01-01 Roggeri, D. P.; Roggeri, A.; Jommi, C.
Costs of patients suffering from multiple sclerosis in piedmont region: Evidence from administrative databases
2012-01-01 Roggeri, D. P.; Roggeri, A.; Jommi, C.